Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Denali Therapeutics Inc
(NQ:
DNLI
)
15.56
-0.55 (-3.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Denali Therapeutics Inc
< Previous
1
2
Next >
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
February 27, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces $500 million Private Placement Equity Financing
February 27, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
February 07, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
February 01, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 08, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 07, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
August 30, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
June 20, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
May 18, 2023
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Via
MarketBeat
Exposures
Product Safety
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 08, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
April 12, 2023
Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
April 10, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
February 27, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
February 22, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
February 15, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
January 25, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 09, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
December 05, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
November 01, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 24, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
October 19, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Proposed Offering of Common Stock
October 18, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
October 03, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
June 29, 2022
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...
Via
FinancialNewsMedia
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
June 07, 2022
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still...
Via
FinancialNewsMedia
Exposures
COVID-19
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
June 22, 2022
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...
Via
FinancialNewsMedia
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
March 31, 2022
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia...
Via
FinancialNewsMedia
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.